Hepta

Hepta Therapeutics is a Tokyo-based biotechnology company focused on revolutionizing drug discovery for G protein-coupled receptors (GPCRs). The company's core technology, the Hepta-S platform, allows for the stabilization of GPCRs in their active states, overcoming traditional challenges in structural analysis and ligand screening. This approach enables the identification of highly selective small molecules and antibodies against previously undruggable GPCR targets. Hepta Therapeutics primarily targets therapeutic areas such as metabolic diseases, oncology, and inflammation. By combining structural biology with computational design, the company aims to build a robust pipeline of first-in-class and best-in-class therapies.